Navigation Links
Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Date:7/29/2008

42-1687 (domestic) or 706-645-9291 (international) and reference the conference ID 58102479. A live audio webcast of the call and the archived webcast will be available in the Investors section of the Echo Therapeutics website http://www.echotx.com .

About Echo Therapeutics

Echo Therapeutics is focused on transdermal medical devices and specialty pharmaceuticals. Echo is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for diabetics and for use in hospital critical care units, together with a wide range of novel transdermal reformulations of FDA-approved products.

Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies regarding the efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's tCGM systems, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic products based on its skin permeation platform technologies, including the Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, and regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its tCGM systems.

These and other factors are identified
'/>"/>

SOURCE Echo Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Fla. , Sept. 2, 2015   Voalte ... a new capital infusion of $17 million by ... Cerner Corporation, and Bedford Funding. Series D funding closed ... has raised to nearly $60 million in three years. ... sustain a triple-digit growth trajectory for Voalte. The privately ...
(Date:9/2/2015)... China, Sept. 2, 2015 China Nepstar Chain ... "Company"), a leading retail drugstore chain in China based ... its unaudited financial results for the second quarter ended ... ended June 30, 2015: , Revenue increased by ... million in the second quarter of 2014 , ...
(Date:9/1/2015)... On August 31, 2015, United States District ... 123-page order in the first of the consolidated MDL ... replacement devices are defective.[1]  The Court ... Robyn Christiansen,s claims for defective design, fraudulent misrepresentation and ... Medical,s claim that the Medical Device Amendment to the ...
Breaking Medicine Technology:Voalte Raises $17 Million in Series D Financing 2Voalte Raises $17 Million in Series D Financing 3Voalte Raises $17 Million in Series D Financing 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 10Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 2Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 3
... /PRNewswire/ -- Portola,Pharmaceuticals, Inc. announced positive Phase ... oral Factor Xa inhibitor, today at the ... and Haemostasis,(ISTH) in Geneva, Switzerland. The EXPERT ... well tolerated for the,prevention of venous thromboembolic ...
... for U.S. Trial -, MISSISSAUGA, ON, ... Inc. , an oncology company that ... patients worldwide,today announced results of secondary ... placebo-controlled, multi-center Phase IIb,trial (DLXLEF-AP4) with ...
Cached Medicine Technology:Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 3Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 4YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 2YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 3YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 4YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 5
(Date:9/2/2015)... ... September 02, 2015 , ... The Hydration ... allopathic medicine, opens its second location this week at 31542 S. Coast Hwy, ... feet of lounge space for patients to relax while receiving safe and effective ...
(Date:9/2/2015)... Burnsville, MN (PRWEB) , ... September 02, 2015 , ... ... forward to it; others dread it. However, few are prepared to face the academic ... once school starts. Our schools haven’t prepared them since schools don’t teach students how ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the upper extremity surgical market, announced today that more than 600 successful patient ... in the hand. Plus, nearly 70 of these procedures have been on ...
(Date:9/2/2015)... ... September 02, 2015 , ... Lakeview Health, a nationally recognized ... Overdose Awareness Day. The goal is to provide people information regarding drugs and ... they may get help. , Lakeview Health will be publishing information ...
(Date:9/2/2015)... PA (PRWEB) , ... September 02, 2015 , ... Pentec ... prestigious 2015 Inc. 5000 List for an impressive sixth consecutive year. Less than 5 ... with only twelve firms in the “health” sector. Pentec’s 3-year revenue growth rate ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... Tenn., Jan. 13 The National Eczema Association,(NEA) awarded ... Lotion. , The NEA Seal ... Education (EASE) program, which is intended to improve the,quality ... eczema and sensitive,skin. , "These ...
... now open for a more rewarding challenge , ... Jenkintown, PA (PRWEB) January 13, 2009 ... resolutions and according to USA.gov, losing weight and getting fit are among the ... many of those eager to fulfill their vows is to lace up their ...
... to meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical ... 2009-2010 season beginning in August. , ... (Vocus) January ... the Flu Vaccine for the 2009-2010 flu season. ...
... persistence to seek out the best treatment options available ... leg today. Bill,s proactive efforts led him to revolutionary ... Methodist Hospital, in Columbus, Ohio, where a team of ... During the minimally invasive procedure, they also found and ...
... announces the launch of their new website www.GlaceComplete.com . ... to Glenwood Systems and the company,s turbo-charged practice management/billing system GlaceComplete ... information. , ... Waterbury, CT (PRWEB) January Monday 12, ...
... of the 21,000 Americans who die each year of ... likely cause. So, the American Association of ... Cancer Survivors Against Radon (CanSAR) with a ... those who never smoked. Those making the connection, along ...
Cached Medicine News:Health News:National Eczema Association Anoints Theraplex Child-Friendly Eczema Products with Seal of Acceptance 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 3Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 4Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 3Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 4Health News:Glenwood Systems, LLC Launches New Website -- GlaceComplete.com 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 3Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 4
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: